Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q2 2024 Earnings Presentation
9 slides from Phibro Animal Health's earnings presentation, Feb 8, 2024
Slide 1: Phibro Animal Health Corporation Webcast and Conference Call
Phibro Animal Health Corporation Webcast and Conference Call February 8, 2024 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2024 Second Quarter Ended December 31, 2023 February 8, 2024 Webcast and Conference Call
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to future debt and leverage levels. All statements other than statements of historical or current
Slide 3: Key Themes
Key Themes Three months ended December 31, 2023 Strong growth in Second Half Guidance affirmed for Animal Health expectations adjusted items Animal Health sales and Continuing Animal Health growth Affirming fiscal year adjusted EBITDA growth of 6% 2024 guidance and 6%, respectively. Recovery in Mine
Slide 4: Financial Performance - Consolidated
Financial Performance - Consolidated Second Quarter, Year-on-Year comparison $ in millions, except per share data • Net Sales – +$5.3 million, or 2%. Animal Health +6%; declines in YOY Mineral Nutrition and Performance Products Q2 %∆ • Net Income & Diluted EPS – Net income decreased $5.9 million o F
Slide 5: Financial Performance – Animal Health
Financial Performance – Animal Health Second Quarter, Year-on-Year comparison $ in millions Net Sales +$9.3 million, or 6% YOY • Vaccines +$7.0 million, or 31% Q2 %∆ • poultry product introductions in Latin America Animal Health • increased domestic demand • Nutritional specialties $(2.4) million, o
Slide 6: Financial Performance – Other Segments
Financial Performance – Other Segments Second Quarter, Year-on-Year comparison $ in millions YOY • Mineral Nutrition Q2 %∆ - Net sales down $(0.3) million, or less than 1% Mineral Nutrition o declines in average selling prices Net Sales $ 61.3 (0%) o some reduction in sales volume Adj. EBITDA $ 3.5
Slide 7: Key Capitalization Metrics
Key Capitalization Metrics December 31, 2023 Free cash flow was $37 million for the TTM -- positive cash from operating activities of $74 million, less capital expenditures of $(37) million. Free Cash Flow (1) Cash and cash equivalents and short-term investments of $92 million as of December 31, 202
Slide 8: Financial Guidance
Financial Guidance Fiscal Year 2024 $ in millions, except earnings per share (EPS) data FY 2023 FY 2024 Full Year Guidance • Affirming fiscal-year 2024 guidance for net sales, Actual Low High adjusted EBITDA, adjusted net income and adjusted diluted EPS Consolidated Net Sales $ 978 $ 980 $ 1,020 Net
Slide 9: Q&A
PAHC Company Overview Q&A 9 February 8, 2024 Webcast and Conference Call